News & Updates
Filter by Specialty:
VELO supports liquid biopsy-guided anti-EGFR rechallenge therapy in mCRC
12 Sep 2023
byAudrey Abella
In the phase II VELO trial, third-line (3L) treatment with the anti-EGFR* monoclonal antibody (mAb) panitumumab and standard of care (SoC) improved progression-free survival (PFS) in patients with refractory RAS wild-type metastatic colorectal cancer (WT mCRC).
VELO supports liquid biopsy-guided anti-EGFR rechallenge therapy in mCRC
12 Sep 2023
Triple G agonist shows therapeutic potential in obesity
11 Sep 2023
Treatment with retatrutide, the novel agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, leads to marked reductions in body weight in individuals with obesity, as shown in the results of a phase II trial.
